Proteins and Peptides

05 Jun 2017 Halozyme Phase 2 Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO
04 Jun 2017 Endocyte Announces Clinical Updates for EC1456 and EC1169
04 Jun 2017 ARMO BioSciences Announces Encouraging Survival Data Observed in Patients with Advanced Pancreatic Cancer in Phase 1/1b Trial of Immunotherapy AM0010
04 Jun 2017 ARMO BioSciences Announces Promising Response Rates and Survival Data in Patients with Advanced NSCLC and RCC from Phase 1/1b Trial for Immunotherapy AM0010 with Checkpoint Inhibitors
04 Jun 2017 Pieris Pharmaceuticals Announces Presentation of Clinical Data for Anemia Drug Candidate, PRS-080, at the 54th ERA-EDTA Congress
02 Jun 2017 European Commission Approves Brineura™ (cerliponase alfa), the First Treatment for CLN2 Disease, a Form of Batten Disease and Ultra-Rare Brain Disorder in Children
01 Jun 2017 Novo Nordisk receives US FDA approval of REBINYN® (nonacog beta pegol; N9-GP)
30 May 2017 Molecular Partners provides additional details on clinical studies of proprietary lead oncology asset MP0250
28 May 2017 Novo Nordisk submits application in the US for including data from the DEVOTE trial in the Tresiba® label
26 May 2017 Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300
26 May 2017 FDA Advisory Committee Recommends Approval of Pfizer’s Proposed Biosimilar to Epogen®/Procrit® Across All Indications
25 May 2017 Radius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS™ in Postmenopausal Women with Osteoporosis
24 May 2017 Spyryx Biosciences Reports Positive Data on SPX-101 at American Thoracic Society International Conference
23 May 2017 Ultragenyx Announces Recombinant Human Beta-Glucuronidase Biologics License Application and Marketing Authorization Application Filed and Accepted for Review; FDA Grants Priority Review Status
23 May 2017 Dompé Receives Positive CHMP Opinion in Europe For Oxervate® (Cenegermin Eye Drops) For the Treatment of Adult Patients with Moderate or Severe Neurotrophic Keratitis
23 May 2017 Atox Bio's Reltecimod Passes Futility Analysis in Phase 3 ACCUTE Study; Trial Continues as Planned
23 May 2017 Positive Phase 2a results with microdoses of dasiglucagon support use in a dual-hormone artificial pancreas system
23 May 2017 Bydureon EXSCEL trial meets primary safety objective in type-2 diabetes patients at wide range of cardiovascular risk
22 May 2017 AM-Pharma Completes Patient Recruitment of Recombinant Human Alkaline Phosphatase (recAP) Phase II Trial in Acute Kidney Injury
22 May 2017 Xenetic Biosciences Receives Program Update from Partner Shire’s Phase 1/2 Study Evaluating SHP656 in Development as a Long-acting Treatment for Hemophilia A
21 May 2017 Sanofi Receives CHMP Recommendation for Approval of Insulin Lispro Biosimilar
19 May 2017 Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial
19 May 2017 MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers
18 May 2017 Aurinia Doses First Patient in AURORA Phase 3 Clinical Trial of Voclosporin in Lupus Nephritis
17 May 2017 Rhythm Expands Phase 2 Clinical Trials of Setmelanotide to the Treatment of Bardet-Biedl Syndrome Obesity

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing